NovImmune SA
64 avenue de la Roseraie
Geneva
1211
Tel: 41-22-839-71-41
Fax: 41-22-839-71-42
Website: http://www.novimmune.com/
45 articles with NovImmune SA
-
Sobi Acquires Emapalumab and Related Assets
6/12/2019
The acquisition means that the previously announced exclusive licence agreement with Novimmune will be superseded.
-
Sobi and Novimmune Selected as Honourees for 2019 National Organization for Rare Disorders (NORD) Rare Impact Award in Industry Innovation for Gamifant® (emapalumab)
3/25/2019
Sobi™ and Novimmune SA have both been selected as honourees by the National Organization for Rare Disorders for the 2019 Rare Impact Awards.
-
New Emapalumab Data Presented at Transplantation and Cellular Therapy (TCT) Meeting Highlight Post-transplant Treatment Outcomes in Primary HLH
2/26/2019
Swedish Orphan Biovitrum AB and Novimmune SA announced the presentation of late-breaking data from the phase 2/3 clinical study of emapalumab-lzsg in primary haemophagocytic lymphohistiocytosis at the 2019 Transplantation and Cellular Therapy Meetings, February 20-24 in Houston, Texas.
-
Data Presented at ASH Support Emapalumab as an Innovative, Targeted Therapeutic Option for Primary HLH
12/4/2018
Swedish Orphan Biovitrum AB (publ) (Sobi™) and Novimmune SA are presenting data from the pivotal phase 2/3 clinical study of emapalumab-lzsg in primary haemophagocytic lymphohistiocytosis (HLH) as part of the late-breaking abstract session at the 60th Annual Meeting of the American Society of Hematology (ASH), taking place 1-4 December 2018, in San Diego.
-
Late-breaking Abstract at ASH Supports Evidence on Transformative First-ever Treatment in Primary HLH
11/22/2018
Swedish Orphan Biovitrum AB (publ) (Sobi™) and Novimmune SA are pleased to announce that the abstract "Safety and efficacy of emapalumab in paediatric patients with primary hemophagocytic lymphohistiocytosis" was accepted as a late-breaking abstract at the 60th Annual Meeting of the American Society of Hematology in San Diego, California, 1-4 December 2018, for oral presentation.
-
Sweden-based Sobi and Swiss-based Novimmune announced the U.S. approval of Gamifant (emapalumab-lzsg) to treat an ultra-rare disease in adults and children. Sobi’s U.S. offices are in Waltham, Mass.
-
FDA Approves Gamifant® (emapalumab-lzsg), the First and Only Treatment Indicated for Primary Hemophagocytic Lymphohistiocytosis (HLH)
11/20/2018
Primary HLH is an ultra-rare syndrome of hyper-inflammation that usually occurs within the first year of life and can rapidly become lethal unless diagnosed and treated
-
Overall, the Swiss-based Roche announced a group sales increase of 7 percent, with the Pharmaceuticals Division up 7 percent, largely driven by sales of Ocrevus, Perjeta, Alecensa and Tecentriq.
-
Sobi™ strengthens inflammation franchise by acquiring global rights for emapalumab from Novimmune
7/20/2018
Swedish Orphan AB, an international biopharmaceutical company dedicated to rare diseases, and NovImmune SA have entered into an exclusive licence agreement for the perpetual global rights to emapalumab, a late-stage orphan drug candidate for the treatment of primary Haemophagocytic lymphohistiocytosis, developed by Novimmune SA, a privately-held, pre-commercial drug discovery and development company focused on rare inflammatory diseases, immune disorders and immuno-oncology.
-
TG Therapeutics and Novimmune SA struck a collaborative deal worth up to $185 million on the development and commercialization of a treatment for hematologic B-cell malignancies.
-
Nordic Nanovector Strengthens Management Team With Appointment of Maureen Deehan, PhD, as Head of Corporate Development and Strategy
6/1/2018
Nordic Nanovector ASA (OSE: NANO) announces that Maureen Deehan, PhD, has been appointed as Head of Corporate Development and Strategy.
-
Shire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement For NovImmune SA Bi-Specific Antibody
7/18/2017
-
NovImmune SA's NI-0501 Granted Breakthrough Therapy Designation By U.S. FDA For Treatment Of Patients With Primary Hemophagocytic Lymphohistiocytosis (HLH)
3/16/2016
-
NovImmune SA Completes CHF30 Million ($29.8 Million) Funding Round With Existing Shareholders
1/12/2016
-
Former Roche Exec Joins NovImmune SA as New CEO
12/21/2015
-
NovImmune SA Abstract Selected For The "Best Of ASH" At The 2015 Annual Meeting Of American Society of Hematology (ASH)
12/16/2015
-
NovImmune SA's Experimental Drug Selected For Oral Presentation At 2015 Annual Meeting Of American Society of Hematology
12/2/2015
-
NovImmune SA’s Experimental Drug Selected For Oral Presentation At 2015 Annual Meeting Of American Society of Hematology
12/1/2015
-
NovImmune SA's New Rheumatoid Arthritis Drug Clears Regulatory Hurdles
11/3/2015
-
NovImmune SA Announces Presentations At 2015 American College of Rheumatology Annual Meeting
11/3/2015